Company intelligence / Profile preview

Tolanoa

Ownership: Private
Development stage: Other

Overview

Tolero’s lead compound alvocidib, a CDK9 inhibitor licensed from Sanofi, demonstrated proof-of-concept in randomized Phase 2 studies for AML and received Orphan Drug Designation from both FDA and EMA. Additional assets include an oral prodrug version of alvocidib and other kinase inhibitors targeting oncology indications. The company was acquired by Sumitomo Dainippon Pharma for up to $780 million to strengthen its oncology pipeline.

Therapeutic areas: HematologyOncology
Modalities: Small moleculeKinase inhibitorProdrug
Industry: Biotech

Partnerships

Sanofi S.A.

Beyond the preview

Go deeper on Tolanoa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tolanoa.

Explore the full profile